EP3297617A1 - Compositions de cannabis homogènes et leurs procédés de production - Google Patents

Compositions de cannabis homogènes et leurs procédés de production

Info

Publication number
EP3297617A1
EP3297617A1 EP16796872.6A EP16796872A EP3297617A1 EP 3297617 A1 EP3297617 A1 EP 3297617A1 EP 16796872 A EP16796872 A EP 16796872A EP 3297617 A1 EP3297617 A1 EP 3297617A1
Authority
EP
European Patent Office
Prior art keywords
composition
oil
cannabis
cannabinoid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16796872.6A
Other languages
German (de)
English (en)
Other versions
EP3297617A4 (fr
Inventor
Jeremy H. GOLDSTEIN
Justin Eric SINGER
Adrian VERWOLF
Garret Nicodemus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
5071 Inc
Original Assignee
5071 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 5071 Inc filed Critical 5071 Inc
Priority claimed from PCT/US2016/025044 external-priority patent/WO2016186735A1/fr
Publication of EP3297617A1 publication Critical patent/EP3297617A1/fr
Publication of EP3297617A4 publication Critical patent/EP3297617A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • This disclosure relates to the cannabis industry.
  • the disclosure relates to cannabis compositions for use in the making beverages, methods of making beverages, and beverages.
  • Cannabis has a long history of being consumed for many purposes and in many forms.
  • the psychoactive effects of cannabis are well known, however the medical benefits are just as useful. Treating glaucoma, pain management, appetite stimulation and easing anxiety are just a few of the potential benefits.
  • the source of these effects are in the cannabinoids, a class of compounds found exclusively in the cannabis plant.
  • cannabinoids a class of compounds found exclusively in the cannabis plant.
  • THC tetrahydrocannabniol
  • CBD cannabidiol
  • CBD is also another major cannabinoid comprising up to 40% of cannabis extract and could have as many health benefits as THC.
  • a common method is alcohol extraction. Using a solvent to extract the cannabinoids and then evaporating the alcohol leaving a resin. Further extraction and evaporation can yield a product that is closer to a solid.
  • Another common method for the purposes of making edibles is placing the cannabis leaves in butter, heavy cream, oil, etc. and then heating to extract the
  • cannabinoids The end product is then used as an ingredient in baking or cooking which usually results in a high caloric food due to the fat needed to extract the cannabinoids.
  • Cannabinoids are soluble in fats and alcohols. Which is why when making cannabis tea the cannabinoids have to be already extracted. Just placing cannabis leaves in hot water will not effectively extract any of the vital
  • these new cannabis compositions are beverages, such as tea.
  • these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.
  • the disclosed cannabis compositions are homogenous.
  • the disclosed cannabis compositions include a surfactant and a carrier oil.
  • the disclosed cannabis compositions are consistent with respect to cannabinoid amount.
  • the disclosed cannabis compositions are low-calorie cannabis beverages, such as low calorie cannabis teas.
  • compositions comprising:
  • cannabinoid refers to a compound that acts on the cannabinoid receptor.
  • the compositions are low does compositions having 0.1 to 10 mg of cannabinoid. In some embodiments, the composition comprises between 0.5 to 5 mg.
  • cannabinoid can be used, such as more than 10 mg, for example 20 - 500 mg or 50 - 200 mg.
  • cannabinoids are tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabicyclol, cannabivarin, cannabielsoin, cannabicitran, cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol monomethylether, cannabigerovarinic acid, cannabigerovarin, cannabichromenic acid, cannabichromevarinic acid, cannabichromevarin, cannabidolic acid, cannabidiol monomethylether, cannabidiol-C 4 , cannabidivarinic acid,
  • cannabidiorcol delta-9-tetrahydrocannabinolic acid A, delta-9- tetrahydrocannabinolic acid B, delta-9-tetrahydrocannabinolic acid-C 4 , delta-9- tetrahydrocannabivarinic acid,delta-9-tetrahydrocannabivarin, delta-9- tetrahydrocannabiorcolic acid, delta-9-tetrahydrocannabiorcol,delta-7-cis-iso- tetrahydrocannabivarin, delta-8-tetrahydrocannabiniolic acid, delta-8- tetrahydrocannabinol, cannabicyclolic acid, cannabicylovarin, cannabielsoic acid A, cannabielsoic acid B, cannabinolic acid, cannabinol methylether, cannabinol-C 4 , cannabinol-C2, cannabiorcol, 10-
  • THC tetrahydrocannabinol
  • CBD canbidiol
  • surfactant refers to a compound that lowers the surface tension between two liquids or between a liquid and solid.
  • Surfactants can be anionic, cationic, non-ionic and amphoteric.
  • Examples of surfactants are ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perflurooctanoic acid, potassium lauryl sulfate, soap, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laureth sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate, perflurobutanesulfonic acid, perfluorononanoic acid, perlurooactanesulfonic acid, benzalkonium chloride, benzethonium chloride, bronidox,
  • dimethyldioctadecylammonium chloride lauryl methyl gluceth-10 hydroxypropyl dimonium chloride, cetrimonium bromide, cetrimonium chloride,
  • tetramethylammonium hydroxide cetomacrogol 1000, cetostearyl alcohol, cetyl alcohol, cocamide DEA, cocamide MEA, NP-40, octaethylene glycol monododecyl ether, N-octyl beta-D-thoglucopyranoside, octyl glucoside, oleyl alcohol, decyl glucoside, pentaethylene glycol monododecyl ether, poloxamer 407, polyglycerol polyricinolate, polysorbate, polysorabte 20, IGEPAL CA-630, isoceteth-20, lauryl glucoside, lecithin, sodium lauroampoacetate.cocamidopropyl betaine,
  • monododecyl ether nonoxynol-9, monolaurin, oleyl alcohol, poloxamer, sorbitan monostearate, polysorbate 80 and glycerol monostearate.
  • surfactants within the context of this disclosure include polysorbate 80 and/or glycerol monostearate.
  • polysorbate 80 refers to a compound having the following structure:
  • glycol monostearate refers to a compound having the following structure:
  • carrier oil refers to an oil that can be used to form a homogenized mixture with cannabis oil. Examples include coconut oil, palm oil, palm kernel oil, hemp oil, caproic acid and caprylic acid.
  • carrier oils within the context of this disclosure is medium chain triglycerides.
  • a carrier oil within the context of this disclosure is coconut oil.
  • hemp oil Another example of a carrier oil within the context of this disclosure is hemp oil.
  • coconut oil means oil extracted from the kernel or meat of coconuts.
  • coconut is the fruit of the coconut palm.
  • coconut oil is noted for it's high saturated content. Examples include lauric acid, myristic acid, palmitic acid, and decanoic acid.
  • hemp oil refers to oil obtained from hemp seeds. Hemp seeds come from a variety of the Cannabis sativa plant that does not contain a high amount of tetrahydrocannabinol. The oil is about 80% essential fatty acids. Examples inlcude iinolenic acid, omega ⁇ 8, alpha-linoienic acid, and omega-3.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a sugar alcohol.
  • sugar alcohol refers to alcohols prepared from sugars with the general chemical formula HOCH2(CHOH) n CH20H.
  • examples include glycerol, eryihrito!, threitol, arabitol, xylitol, mannitol, r bitoL manniiol, galacitoL fucito!, inositol, opposedmitol, ma!titoL iacitol, malootetraitol, polygiycitol, sorbitol, idito!, isoma!t, and ma!totriitoi.
  • sugar alcohols within the context of this disclosure include g!yceroi/giycerin or sorbitol.
  • glycol refers to a compound having the following structure:
  • sorbitol refers to a compound having the following structure:
  • the composition disclosed herein comprises a cannabinoid, a surfactant, a carrier oil, and a gelling agent.
  • gelling agent means a substance that dissolves in the liquid phase and forms a weak cohesive internal structure.
  • Examples include natural gums, starches, pectins, agar-agar, and gelatin.
  • gelatin refers to a gelling agent derived from the collagen of various all byproducts.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has less than 10 mass% water.
  • the composition is a solid. In one embodiment, the composition is a granual.
  • the term “less than 10 mass% water” means less than 10% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has more than 95 mass% water.
  • the term “more than 95 mass% water” means less than 95% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a flavoring agent.
  • flavoring agent means a compound that adds a flavor to a composition.
  • flavoring agents include amyl acetate, benzaldehyde, ethyl butyrate, methyl anthranilate, methyl salicylate, fumaric acid, di acetyl, cinnamaldehyde, ethyl propionate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, ethylvanillin, and methyl salicylate.
  • the composition comprises a coloring agent.
  • coloring agent means any substance that adds or changes the color of the substance to which the coloring agent is added.
  • examples of the term coloring agent include any dye, pigment or substance that imparts color when it is added to food or drink.
  • the coloring agent can be natural or non-natural. Such agents come in many forms, including liquids, powders, gels, dyes, lakes, and pastes.
  • one or more coloring agents can be added to the compositions of this disclosure to match the coloring between two ingredients.
  • brownish color is added to a compositions comprising a cannabinoid, a surfactant, and a carrier oil in order to make the said compositions take on the color of natural tea.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and tea.
  • the tea are tea leaves.
  • the term "tea” is meant to include any composition that is similar or labeled as tea, either natural or synthetic. Tea refers to both artificially flavored and/or artificially colored compositions in addition to all forms of natural tea leaves. In one embodiment, the cannabis compositions are brown granules.
  • tannin leaves refers to forms of the plant Camellia sinensis.
  • the composition comprises less than 4 grams of caloric mass. In one embodiment the caloric mass is less than 2 grams.
  • caloric mass means mass metabolized by humans to generate energy. Examples include carbohydrates and proteins which give 4 cal/gram and fats which give 9 cal/gram.
  • the composition comprises 0.5 to 5 mg of the cannabinoid is present in a consistent amount, having less than 0.2 mg of deviation across sample portions of the composition.
  • the terrri'consistent amount means a collection of samples would all have relatively similar amounts of the cannabinoid. Similar means limited amount of deviation in the mass of the cannabinoid. For example, if a collection of compositions were analyzed to determine the mass of
  • each sample in that collection would have a similar mass of cannabinoid present in relation to the total amount of each composition.
  • the composition comprises:
  • cannabis oil having 1 .5 to 3.5 mg of THC
  • the composition comprises:
  • cannabis oil having 1 .5 to 3.5 mg of THC
  • the composition comprises:
  • cannabis oil having 1 .5 to 3.5 mg of THC
  • the composition comprises:
  • cannabis oil having 1 .5 to 3.5 mg of THC
  • the gram amounts of ingredients depend on the batch size. Gram amounts for batches can be determined by following the mixing guidelines below.
  • Carrier oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
  • Glycerol monostearate and polysorbate 80 were added to a beaker and heated to 80 C with a hot plate for 10 minutes to provide a homogeneous surfactant blend.
  • Carrier oil and CBD oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.
  • Carrier oil and cannabis oil were added to the surfactant blend and stirred for 10 minutes at 60 C, to provide a homogenous mixture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de nouvelles compositions de cannabis. Dans un mode de réalisation, ces nouvelles compositions de cannabis sont des boissons, telles que du thé. Dans un mode de réalisation, ces nouvelles compositions de cannabis sont des boissons déshydratées, telles que des poudres ou des formes cristallines, qui peuvent être mélangées avec d'autres constituants, comme du thé, et ajoutés dans de l'eau.
EP16796872.6A 2015-05-18 2016-03-30 Compositions de cannabis homogènes et leurs procédés de production Pending EP3297617A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163316P 2015-05-18 2015-05-18
PCT/US2016/025044 WO2016186735A1 (fr) 2015-05-18 2016-03-30 Compositions de cannabis homogènes et leurs procédés de production

Publications (2)

Publication Number Publication Date
EP3297617A1 true EP3297617A1 (fr) 2018-03-28
EP3297617A4 EP3297617A4 (fr) 2019-02-20

Family

ID=61223555

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16796872.6A Pending EP3297617A4 (fr) 2015-05-18 2016-03-30 Compositions de cannabis homogènes et leurs procédés de production

Country Status (1)

Country Link
EP (1) EP3297617A4 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
CN101904401A (zh) * 2010-07-09 2010-12-08 云南龙润茶业集团有限公司 一种茶凝胶软糖
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
US9326967B2 (en) * 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
WO2015191728A1 (fr) * 2014-06-11 2015-12-17 Poviva Tea, Llc Compositions d'aliments et de boissons dans lesquelles ont été infusées des cannabinoïdes, et leurs procédés d'utilisation

Also Published As

Publication number Publication date
EP3297617A4 (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
US12225913B2 (en) Cannabis compositions and methods of making the same
Pereira et al. Culinary and nutritional value of edible wild plants from northern Spain rich in phenolic compounds with potential health benefits
Patra et al. Microwave-assisted extraction of sea buckthorn pomace and seed extracts as a proactive antioxidant to stabilize edible oils
Medina‐Torres et al. Study of the antioxidant properties of extracts obtained from nopal cactus (Opuntia ficus‐indica) cladodes after convective drying
Cerda-Tapia et al. Valorization of pomace powder obtained from native Mexican apple (Malus domestica var. rayada): chemical, techno-functional and antioxidant properties
Inikpi et al. Volatile composition of the floral essential oil of Hibiscus sabdariffa L. from Nigeria
Begmeier et al. Extraction of total polyphenols from hibiscus (Hibiscus sabdariffa L.) and waxweed/‘sete-sangrias’(Cuphea carthagenensis) and evaluation of their antioxidant potential
JP2004091392A (ja) 水分散用水難溶性成分含有組成物および飲料
CN103652859A (zh) 一种具有抗氧化功能的保健食品及其制备方法
Boukerche et al. Combination of ultrasound, microwave and conventional extraction techniques for roselle (Hibiscus Sabdariffa. L.) total anthocyanins and phenolics recovery: effect on antioxidant and structural properties
Kadda et al. Phytochemical analysis for the residues of Opuntia ficus indica l seed oil of eastern region of Morocco
Sundarraj et al. Phytochemical screening and spectroscopy analysis of jackfruit (Artocarpus integer Thumb.) peel
KR20140055348A (ko) 인삼의 씨 추출물과 이를 포함하는 조성물 또는 유지 및 이것의 제조방법
Cardoso et al. Green ultrasound-assisted extraction of bioactive compounds from Cumari-Do-Pará Peppers (Capsicum chinense Jacq.) employing vegetable oils as solvents
Mann et al. Value addition scenario of arid foods of desert area and evaluation of their nutritional and phytochemical potential
EP3297617A1 (fr) Compositions de cannabis homogènes et leurs procédés de production
Prajapati et al. Extraction and use of bioactive components from underutilized horticultural crops
Nguyen et al. Applicability of convection drying process for production of instant tea powder from Condonopsis javanica root extract
Moke et al. Phytopharmacological Activities of Spondias mombinLinn: A Review: http://www. doi. org/10.26538/tjpps/v3i1. 1
CN104306290A (zh) 一种茶油bb霜及其制备方法
Ordaz-Trinidad et al. Patents on phytochemicals: methodologies of extraction, application in food and pharmaceutical industry
CN106065367A (zh) 抗氧化食用油及其制备方法和应用
JP2011161374A (ja) 溶解補助剤
Silva et al. Bromatological analysis, phytochemical and antioxidant potential of carnauba (Copernicia prunifera (Mill.) HE Moore) fruit
JP7075575B2 (ja) 脂質代謝改善用又は肝臓脂質蓄積抑制用の食品組成物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/10 20060101ALI20190109BHEP

Ipc: A61K 31/05 20060101ALI20190109BHEP

Ipc: A23L 2/52 20060101ALI20190109BHEP

Ipc: A61K 9/16 20060101AFI20190109BHEP

Ipc: A61K 31/352 20060101ALI20190109BHEP

Ipc: A23F 3/14 20060101ALI20190109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230102